RJA
UTHR icon

Ross\Johnson & Associates’s United Therapeutics UTHR Stock Holding History

Ross\Johnson & Associates’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2
Closed -$617 – 341
2025
Q1 		$617 Buy
+2
New +$685 0.01% 236

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Ross\Johnson & Associates's UTHR Position: Q2 2025 in Review

Ross\Johnson & Associates sold out of United Therapeutics (UTHR) in Q2 2025, closing a stake of 2 shares — an estimated $617 sold.

Ross\Johnson & Associates first reported a position in UTHR in Q1 2025 and held it in 1 quarter. The position peaked at $617 in Q1 2025. 670 funds tracked by Wall St. Rank hold UTHR as of Q2 2025.

  • Ross\Johnson & Associates reported no remaining United Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Ross\Johnson & Associates sold 2 United Therapeutics shares in Q2 2025, an estimated $617.
  • Ross\Johnson & Associates first reported a position in United Therapeutics in Q1 2025 and held it in 1 quarter.
  • Ross\Johnson & Associates's United Therapeutics position peaked at $617 in Q1 2025.
  • 670 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2025.

Based on Ross\Johnson & Associates's 13F filing for Q2 2025, filed 15 Aug 2025.